ECOCAPTURE: Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Unknown status
CT.gov ID
NCT03272230
Collaborator
(none)
135
1
5
53.7
2.5

Study Details

Study Description

Brief Summary

Apathy can be defined as a quantitative reduction of voluntary or goal-directed behavior.

So, the investigators propose a behavioral approach for assessing apathy, to obtain a quantifiable and objective signature of reduced goal-directed behavior by directly observing a patient in a real-life situation.

ECOCAPTURE consists of a multi-step scenario in a functional exploration platform equipped with data acquisition system based on video and sensors that track a participant's behavior.

The primary objective of this trial is to create a diagnostic tool for apathy, based on the video and sensors metrics.

A secondary objective of this trial is to validate a new experimental task (ICM_APATHY_TASKS) to test independently three main presumed mechanisms of apathy (motivation, cognitive inertia and coupling between motivation and action).

Another secondary objective aims to specify the pathophysiological mechanisms of apathy, corresponding to cognitive and behavioral processes, neural bases and neurohormonal mechanisms. The definition of pathophysiological mechanisms will allow the classification of apathetic patients (or several forms of apathy) and indicate which mechanism (s) best explains the apathy in a given patient.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: ECOCAPTURE
  • Behavioral: Cognitive and Behavioral experimental tasks
  • Diagnostic Test: Neuropsychological assessment
  • Behavioral: ICM_APATHY_TASKS
  • Other: MRI
  • Biological: Neurohormonal mechanisms
  • Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease
N/A

Detailed Description

A pilot study ECOCAPTURE (ClinicalTrials.gov/NCT02496312, 2015) applied to a group of participants with the behavioural variant of frontotemporal lobar degeneration (bvFTLD) matched for age, gender and level of education to healthy participants (n=7 per group). This pilot validated the concept of ECOCAPTURE.

The purpose of this trial is to continue the implementation of the ECOCAPTURE tool, extending it to three pathological models: bvFTLD, Parkinson's disease and depression.

The objectives aim to assess behavior directed towards a goal and identify apathy, analyze data to obtain a behavioral signature of apathy and to produce more finely differentiated apathetic patients profiles by specifying the pathophysiological mechanisms (cognitive mechanisms, as well as the neural bases and the neuro-hormonal mechanisms) underlying apathy.

The investigators use multimodal recording tools to track behavior. A multiple-camera system is set up with video coverage of the whole room. A sensor (Move II, Movisens, Karlsruhe, Germany) fixed to the subject's hip, records data such as 3D acceleration, barometric pressure and temperature. From these data, secondary parameters like activity class, body position, steps, energy expenditure and metabolic equivalents are calculated. Video data analysis is performed with The Observer XT software (Noldus, Wageningen, The Netherlands) using an ethogram to identify the frequency and duration of behaviors. For 10 min, during the experimental session, participants ware eye-tracking glasses (ETG 2w, SMI, Teltow, Germany) that record natural gaze behavior.

Metrics built from raw data (video, sensors) are analyzed to reveal a behavioral signature of apathy, highlighting a quantitative reduction in goal-directed behavior.

The study takes place on two visits (one per day). It consists of the observation phase, a neuropsychological assessment, experimental tasks, some of which are computerized, an MRI examination and finally a blood test.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
135 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease
Actual Study Start Date :
Sep 6, 2017
Anticipated Primary Completion Date :
Jul 31, 2019
Anticipated Study Completion Date :
Feb 28, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: bvFTD

Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011). ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms

Behavioral: ECOCAPTURE
45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Behavioral: Cognitive and Behavioral experimental tasks
Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Diagnostic Test: Neuropsychological assessment
MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS

Behavioral: ICM_APATHY_TASKS
Apathy experimental task

Other: MRI
T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI

Biological: Neurohormonal mechanisms
Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage

Experimental: Healthy control

Healthy age, sex and education matched controls ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms

Behavioral: ECOCAPTURE
45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Behavioral: Cognitive and Behavioral experimental tasks
Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Diagnostic Test: Neuropsychological assessment
MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS

Behavioral: ICM_APATHY_TASKS
Apathy experimental task

Other: MRI
T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI

Biological: Neurohormonal mechanisms
Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage

Experimental: Parkinson's disease without Impulse Control Disorders (ICDs)

Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms

Behavioral: ECOCAPTURE
45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Behavioral: Cognitive and Behavioral experimental tasks
Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Diagnostic Test: Neuropsychological assessment
MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS

Behavioral: ICM_APATHY_TASKS
Apathy experimental task

Other: MRI
T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI

Biological: Neurohormonal mechanisms
Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage

Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease
ACDD / QUIP / BIS-11 / ECMP / QUIP-RS

Experimental: Depression

Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV). ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms

Behavioral: ECOCAPTURE
45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Behavioral: Cognitive and Behavioral experimental tasks
Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Diagnostic Test: Neuropsychological assessment
MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS

Behavioral: ICM_APATHY_TASKS
Apathy experimental task

Other: MRI
T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI

Biological: Neurohormonal mechanisms
Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage

Experimental: Parkinson's disease with Impulse Control Disorders (ICDs)

Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications. ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms

Behavioral: ECOCAPTURE
45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system

Behavioral: Cognitive and Behavioral experimental tasks
Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions

Diagnostic Test: Neuropsychological assessment
MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS

Behavioral: ICM_APATHY_TASKS
Apathy experimental task

Other: MRI
T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI

Biological: Neurohormonal mechanisms
Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage

Diagnostic Test: Supplementary Neuropsychological Assessment - Parkinson's Disease
ACDD / QUIP / BIS-11 / ECMP / QUIP-RS

Outcome Measures

Primary Outcome Measures

  1. Occurrence of each behavior from the ethogram [45 min]

    [Provided by the video recording and The Observer NOLDUS software] integer.

  2. Frequency of each behavior from the ethogram [45 min]

    [Provided by the video recording and The Observer NOLDUS software] integer.

  3. Duration of each behavior from the ethogram [45 min]

    [Provided by the video recording and The Observer NOLDUS software] integer.

  4. Number of different behaviors [45 min]

    [Provided by the video recording and The Observer NOLDUS software] integer.

  5. Activity classes [45 min]

    [Provided by the MOVE MOVISENS sensor] lying, sitting, ...

  6. Body positions [45 min]

    [Provided by the MOVE MOVISENS sensor] lying left, ...

  7. Energy expenditure [45 min]

    [Provided by the MOVE MOVISENS sensor] kcal.

  8. MET [45 min]

    [Provided by the MOVE MOVISENS sensor] The Metabolic Equivalent of Task: MET level.

  9. Steps [45 min]

    [Provided by the MOVE MOVISENS sensor] Counting steps.

  10. Acceleration intensity [45 min]

    [Provided by the MOVE MOVISENS sensor] g.

  11. Pupil Diameter x [10 min]

    [Provided by the eye-tracking glasses SMI ETG 2w] mm.

  12. Pupil Diameter y [10 min]

    [Provided by the eye-tracking glasses SMI ETG 2w] mm.

Secondary Outcome Measures

  1. ICM_APATHY_TASKS [At day 1]

    ICM_APATHY_TASKS global score

  2. MMSE [At day 1]

    [Mini Mental State Exam] MMSE global score

  3. MATTIS [At day 1]

    [Mattis Dementia Rating Scale ] MATTIS global score

  4. NART [At day 1]

    [National Adult Reading Test] NART IQ (global score)

  5. BREF (FAB english) [At day 1]

    [Frontal Assessment Battery] BREF global score

  6. HAYLING [At day 1]

    [Hayling Sentence Completion test] ] HAYLING global score

  7. HAD [At day 1]

    [Hospital Anxiety and Depression Scale] ]HAD global score

  8. Gray matter volume [At day 2]

    [MRI analysis- Brain segmentation] mm3

  9. White matter volume [At day 2]

    [MRI analysis- Brain segmentation] mm3

  10. Cerebral Spinal Fluid volume [At day 2]

    [MRI analysis- Brain segmentation] mm3

  11. Brain lesion localization [At day 2]

    [MRI analysis- Brain segmentation] Talairach x,y,z coordinates

  12. IL-6 [At day 1]

    Hormonal result [Interleukin-6] pg/mL

  13. Leptin [At day 1]

    Hormonal result [Leptin] ng/mL

  14. Adiponectin [At day 1]

    Hormonal result [Blood adiponectin level)] mg/L

  15. Insulin [At day 1]

    Hormonal result [Fasting Insulin] mUI/L

  16. C-Peptide [At day 1]

    Diabetic result [Fasting C-Peptide level] µg/L

  17. FPG [At day 1]

    Diabetic result [Fasting Plasma Glucose] mmol/L

  18. HbA1C [At day 1]

    Diabetic result [Glycated Hemoglobin] %

  19. K+ [At day 1]

    Ionogram result [Potassium] mmol/L

  20. Uric acid [At day 1]

    Ionogram result [Uric acid] µmol/L

  21. Creatinine [At day 1]

    Ionogram result [Creatinine] µmol/L

  22. Total Protein [At day 1]

    Ionogram result [Total protein] g/L

  23. CRP [At day 1]

    Inflammatory result [C-reactive protein] mG/L

  24. AST [At day 1]

    Hepatic result [Aspartate aminotransferase] U/L

  25. ALT [At day 1]

    Hepatic result [Alanine aminotransferase] U/L

  26. GGT [At day 1]

    Hepatic result [Gamma-glutamyltransferase] U/L

  27. Cholesterol [At day 1]

    Lipidic result [Total cholesterol] mmol/L

  28. Triglycerides [At day 1]

    Lipidic result [Triglycerides] mmol/L

  29. HDL cholesterol [At day 1]

    Lipidic result [High-density lipoprotein cholesterol] mmol/L

  30. LDL cholesterol [At day 1]

    Lipidic result [Low-density lipoprotein cholesterol] mmol/L

  31. Glycerol [At day 1]

    Lipidic result [Plasma glycerol concentration] mmol/L

  32. FFAs [At day 1]

    Lipidic result [Plasma free fatty acids] mmol/L

  33. TSH [At day 1]

    Thyroid result [Thyroid-stimulating hormone blood test] mmol/L

  34. DAS [At day 1]

    [Dimensional Apathy Scale] DAS global score

  35. STARKSTEIN (SAS) [At day 1]

    [Starkstein Apathy Scale (SAS)] SAS global score

  36. MADRS [At day 1]

    [Montgomery-Åsberg Depression Rating Scale] MADRS global score

  37. EBI [At day 1]

    [Eating Behavior Inventory] EBI global score

  38. ACDD [At day 1]

    [Autoévaluation des Comportements Dopamine Dépendants] ACDD answers

  39. QUIP [At day 1]

    [Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease] QUIP answers

  40. BIS-11 [At day 1]

    [Barratt Impulsiveness Scale] BIS-11 global score

  41. Mini-SEA [At day 1]

    [Mini Social cognition and Emotional Assesment] Mini-SEA global score

  42. STROOP [At day 1]

    [STROOP Test] STROOP global score

  43. ECMP [At day 1]

    [Evaluation Comportementale dans la Maladie de Parkinson] ECMP answers

  44. QUIP-RS [At day 1]

    [Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale] QUIP-RS global score

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
All groups:
  • Ability to give informed consent for study procedures

  • Ability to understand study instructions and to realize the cognitive tasks

  • Person with health insurance

Patients:
  • MMS>20

  • Absence of another neurological or psychiatric disease

  • Presence of a caregiver

  • We will recruit three groups of patients:

  • diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011)

  • diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992)

  • Sub-group 1: Parkinson's disease with Impulse Control Disorders (ICDs)

  • Sub-group 2: Parkinson's disease without Impulse Control Disorders (ICDs)

  • diagnosed with depression (Major Depressive Disorder, DSM-IV)

Healthy age,sex, education-matched controls:
  • MMS>27

  • Absence of neurological or psychiatric disease

Exclusion Criteria:
  • Standard contraindications to MRI

  • Inability to understand study instructions

  • Person mentioned in the article L.1121-5 to L. 1121-8 and L. 1122-12 of the French Public Health Code

Contacts and Locations

Locations

Site City State Country Postal Code
1 ICM / Pitié-Salpêtrière Hospital AP-HP / CIC Paris France 75013

Sponsors and Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Richard LEVY, MD, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT03272230
Other Study ID Numbers:
  • C16-87
  • 2017-A00416-47
First Posted:
Sep 5, 2017
Last Update Posted:
Mar 22, 2019
Last Verified:
Mar 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 22, 2019